<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618967</url>
  </required_header>
  <id_info>
    <org_study_id>20140322</org_study_id>
    <nct_id>NCT02618967</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study of AMG 570 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double Blind Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of AMG 570 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain initial information on the safety and tolerability&#xD;
      (effects good or bad), pharmacokinetics (what the body does to the drug), and&#xD;
      pharmacodynamics (what the drug does to the body) of a single dose of AMG 570.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2016</start_date>
  <completion_date type="Actual">December 3, 2018</completion_date>
  <primary_completion_date type="Actual">September 6, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Day 1 to Day 105</time_frame>
    <description>TEAEs were adverse events with an onset after the administration of study treatment.&#xD;
TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limited age appropriate instrumental activities of daily life (ADL).&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.&#xD;
Serious adverse events (SAEs) were defined as meeting at least 1 of the following criteria:&#xD;
Results in death (fatal)&#xD;
Immediately life-threatening&#xD;
Requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
Results in persistent or significant disability/incapacity&#xD;
Is a congenital anomaly/birth defect&#xD;
Other medically important serious event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced a Clinically Significant Change in Physical Examinations</measure>
    <time_frame>Baseline to Day 105</time_frame>
    <description>Physical examinations were performed by the investigator, designated physician, or nurse practitioner. A complete physical examination included, at a minimum, assessment of cardiovascular, respiratory, gastrointestinal and neurological systems. A brief physical examination included assessment of the skin, lungs, cardiovascular system, and abdomen (liver and spleen).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced a Clinically Significant Change in Vital Signs</measure>
    <time_frame>Baseline to Day 105</time_frame>
    <description>Any changes in blood pressure, body temperature, heart rate, and pulse rate that were deemed as clinically significant by the Investigator were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced a Clinically Significant Change in Clinical Laboratory Safety Tests</measure>
    <time_frame>Baseline to Day 105</time_frame>
    <description>Laboratory safety tests included chemistry, hematology, and urinalysis parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade ≥3 at any post-baseline visit.&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced a Clinically Significant Change in Electrocardiograms (ECGs)</measure>
    <time_frame>Baseline to Day 105</time_frame>
    <description>Any changes in ECG parameters that were deemed clinically significant by the Investigator were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of AMG 570</measure>
    <time_frame>Pre-dose and 12 hours post-dose on Day 1 and days 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 57, 71 and 105</time_frame>
    <description>AMG 570 pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) of AMG 570</measure>
    <time_frame>Pre-dose and 12 hours post-dose on Day 1 and days 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 57, 71 and 105</time_frame>
    <description>AMG 570 PK parameters were estimated using non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast) of AMG 570</measure>
    <time_frame>Pre-dose and 12 hours post-dose on Day 1 and days 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 57, 71 and 105</time_frame>
    <description>AMG 570 PK parameters were estimated using non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve Observed From Time Zero to Infinity (AUCinf) of AMG 570</measure>
    <time_frame>Pre-dose and 12 hours post-dose on Day 1 and days 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 57, 71 and 105</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Anti-AMG 570 Binding Antibody Positive Postbaseline Result</measure>
    <time_frame>Baseline to Day 105</time_frame>
    <description>The presence of anti-AMG 570 binding antibodies was assessed using a validated assay. The number and percentage of participants who developed binding anti-AMG 570 antibodies at any postbaseline visit are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Peripheral Blood B7-Related Protein-1 (B7RP-1) Receptor Occupancy on Total B Cells</measure>
    <time_frame>Day 8; Day 29; Day 57; and Day 105</time_frame>
    <description>Peripheral B7RP1 (also known as inducible costimulator ligand [ICOSL]) receptor occupancy was calculated from the free ICOSL and total ICOSL measurement from B cells in whole blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline for Cluster of Differentiation (CD)19+ Total B Cells Counts</measure>
    <time_frame>Baseline to Day 8; Day 29; Day 57 and Day 105</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline for CD19+ Total B Cells Percentages (%)</measure>
    <time_frame>Baseline to Day 8; Day 29; Day 57 and Day 105</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>AMG 570 - 7 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 570 - 21 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 21 mg dose of AMG 570 administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 570 - 70 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 70 mg dose of AMG 570 administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 570 - 140 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 140 mg dose of AMG 570 administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 570 - 210 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 210 mg dose of AMG 570 administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 570 - 420 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 420 mg dose of AMG 570 administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 570 - 700 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 700 mg dose of AMG 570 administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single dose of the matching AMG 570 placebo administered subcutaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMG 570</intervention_name>
    <description>7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.</description>
    <arm_group_label>AMG 570 - 140 mg</arm_group_label>
    <arm_group_label>AMG 570 - 21 mg</arm_group_label>
    <arm_group_label>AMG 570 - 210 mg</arm_group_label>
    <arm_group_label>AMG 570 - 420 mg</arm_group_label>
    <arm_group_label>AMG 570 - 7 mg</arm_group_label>
    <arm_group_label>AMG 570 - 70 mg</arm_group_label>
    <arm_group_label>AMG 570 - 700 mg</arm_group_label>
    <other_name>Active Comparator, Investigational Product, and Study drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMG 570 Matching Placebo</intervention_name>
    <description>Placebo administered as single dose subcutaneous in healthy volunteers.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo, Investigational Product, and Study drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy as determined by the investigator&#xD;
&#xD;
          -  Normal or clinically acceptable electrocardiogram (ECG)&#xD;
&#xD;
          -  Female subjects must be of documented non-reproductive potential&#xD;
&#xD;
          -  Subjects must be current for all vaccinations&#xD;
&#xD;
          -  Other inclusion criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or chronic history of liver disease&#xD;
&#xD;
          -  History of active infections&#xD;
&#xD;
          -  History of significant respiratory disorder&#xD;
&#xD;
          -  Evidence of renal disease&#xD;
&#xD;
          -  Other exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>November 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <results_first_submitted>August 5, 2021</results_first_submitted>
  <results_first_submitted_qc>September 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 15, 2021</results_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Safety Study</keyword>
  <keyword>Placebo Control</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02618967/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02618967/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 56 healthy participants were enrolled at 3 research centers in the United States from 28 March 2016 to 06 September 2018.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AMG 570 - 7 mg</title>
          <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="P2">
          <title>AMG 570 - 21 mg</title>
          <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="P3">
          <title>AMG 570 - 70 mg</title>
          <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="P4">
          <title>AMG 570 - 140 mg</title>
          <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="P5">
          <title>AMG 570 - 210 mg</title>
          <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="P6">
          <title>AMG 570 - 420 mg</title>
          <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="P7">
          <title>AMG 570 - 700 mg</title>
          <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="P8">
          <title>Placebo</title>
          <description>Participants received a single dose of the matching AMG 570 placebo administered subcutaneously.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set: all participants who received AMG 570 or the placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>AMG 570 - 7 mg</title>
          <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="B2">
          <title>AMG 570 - 21 mg</title>
          <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="B3">
          <title>AMG 570 - 70 mg</title>
          <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="B4">
          <title>AMG 570 - 140 mg</title>
          <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="B5">
          <title>AMG 570 - 210 mg</title>
          <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="B6">
          <title>AMG 570 - 420 mg</title>
          <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="B7">
          <title>AMG 570 - 700 mg</title>
          <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="B8">
          <title>Placebo</title>
          <description>Participants received a single dose of the matching AMG 570 placebo administered subcutaneously.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="14"/>
            <count group_id="B9" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.7" spread="11.4"/>
                    <measurement group_id="B2" value="45.8" spread="14.3"/>
                    <measurement group_id="B3" value="43.2" spread="16.7"/>
                    <measurement group_id="B4" value="42.0" spread="9.8"/>
                    <measurement group_id="B5" value="39.8" spread="17.6"/>
                    <measurement group_id="B6" value="39.8" spread="11.4"/>
                    <measurement group_id="B7" value="40.0" spread="17.1"/>
                    <measurement group_id="B8" value="44.4" spread="12.1"/>
                    <measurement group_id="B9" value="43.1" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs)</title>
        <description>TEAEs were adverse events with an onset after the administration of study treatment.&#xD;
TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limited age appropriate instrumental activities of daily life (ADL).&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.&#xD;
Serious adverse events (SAEs) were defined as meeting at least 1 of the following criteria:&#xD;
Results in death (fatal)&#xD;
Immediately life-threatening&#xD;
Requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
Results in persistent or significant disability/incapacity&#xD;
Is a congenital anomaly/birth defect&#xD;
Other medically important serious event</description>
        <time_frame>Day 1 to Day 105</time_frame>
        <population>Safety analysis set: all participants who received AMG 570 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 570 - 7 mg</title>
            <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>AMG 570 - 21 mg</title>
            <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>AMG 570 - 70 mg</title>
            <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>AMG 570 - 140 mg</title>
            <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>AMG 570 - 210 mg</title>
            <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O6">
            <title>AMG 570 - 420 mg</title>
            <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O7">
            <title>AMG 570 - 700 mg</title>
            <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received a single dose of the matching AMG 570 placebo administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs)</title>
          <description>TEAEs were adverse events with an onset after the administration of study treatment.&#xD;
TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limited age appropriate instrumental activities of daily life (ADL).&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.&#xD;
Serious adverse events (SAEs) were defined as meeting at least 1 of the following criteria:&#xD;
Results in death (fatal)&#xD;
Immediately life-threatening&#xD;
Requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
Results in persistent or significant disability/incapacity&#xD;
Is a congenital anomaly/birth defect&#xD;
Other medically important serious event</description>
          <population>Safety analysis set: all participants who received AMG 570 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 2 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 4 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-threatening TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced a Clinically Significant Change in Physical Examinations</title>
        <description>Physical examinations were performed by the investigator, designated physician, or nurse practitioner. A complete physical examination included, at a minimum, assessment of cardiovascular, respiratory, gastrointestinal and neurological systems. A brief physical examination included assessment of the skin, lungs, cardiovascular system, and abdomen (liver and spleen).</description>
        <time_frame>Baseline to Day 105</time_frame>
        <population>Safety analysis set: all participants who received AMG 570 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 570 - 7 mg</title>
            <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>AMG 570 - 21 mg</title>
            <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>AMG 570 - 70 mg</title>
            <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>AMG 570 - 140 mg</title>
            <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>AMG 570 - 210 mg</title>
            <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O6">
            <title>AMG 570 - 420 mg</title>
            <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O7">
            <title>AMG 570 - 700 mg</title>
            <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received a single dose of the matching AMG 570 placebo administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced a Clinically Significant Change in Physical Examinations</title>
          <description>Physical examinations were performed by the investigator, designated physician, or nurse practitioner. A complete physical examination included, at a minimum, assessment of cardiovascular, respiratory, gastrointestinal and neurological systems. A brief physical examination included assessment of the skin, lungs, cardiovascular system, and abdomen (liver and spleen).</description>
          <population>Safety analysis set: all participants who received AMG 570 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced a Clinically Significant Change in Vital Signs</title>
        <description>Any changes in blood pressure, body temperature, heart rate, and pulse rate that were deemed as clinically significant by the Investigator were reported.</description>
        <time_frame>Baseline to Day 105</time_frame>
        <population>Safety analysis set: all participants who received AMG 570 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 570 - 7 mg</title>
            <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>AMG 570 - 21 mg</title>
            <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>AMG 570 - 70 mg</title>
            <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>AMG 570 - 140 mg</title>
            <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>AMG 570 - 210 mg</title>
            <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O6">
            <title>AMG 570 - 420 mg</title>
            <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O7">
            <title>AMG 570 - 700 mg</title>
            <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received a single dose of the matching AMG 570 placebo administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced a Clinically Significant Change in Vital Signs</title>
          <description>Any changes in blood pressure, body temperature, heart rate, and pulse rate that were deemed as clinically significant by the Investigator were reported.</description>
          <population>Safety analysis set: all participants who received AMG 570 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced a Clinically Significant Change in Clinical Laboratory Safety Tests</title>
        <description>Laboratory safety tests included chemistry, hematology, and urinalysis parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade ≥3 at any post-baseline visit.&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.</description>
        <time_frame>Baseline to Day 105</time_frame>
        <population>Safety analysis set: all participants who received AMG 570 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 570 - 7 mg</title>
            <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>AMG 570 - 21 mg</title>
            <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>AMG 570 - 70 mg</title>
            <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>AMG 570 - 140 mg</title>
            <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>AMG 570 - 210 mg</title>
            <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O6">
            <title>AMG 570 - 420 mg</title>
            <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O7">
            <title>AMG 570 - 700 mg</title>
            <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received a single dose of the matching AMG 570 placebo administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced a Clinically Significant Change in Clinical Laboratory Safety Tests</title>
          <description>Laboratory safety tests included chemistry, hematology, and urinalysis parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade ≥3 at any post-baseline visit.&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.</description>
          <population>Safety analysis set: all participants who received AMG 570 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced a Clinically Significant Change in Electrocardiograms (ECGs)</title>
        <description>Any changes in ECG parameters that were deemed clinically significant by the Investigator were reported.</description>
        <time_frame>Baseline to Day 105</time_frame>
        <population>Safety analysis set: all participants who received AMG 570 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 570 - 7 mg</title>
            <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>AMG 570 - 21 mg</title>
            <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>AMG 570 - 70 mg</title>
            <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>AMG 570 - 140 mg</title>
            <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>AMG 570 - 210 mg</title>
            <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O6">
            <title>AMG 570 - 420 mg</title>
            <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O7">
            <title>AMG 570 - 700 mg</title>
            <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received a single dose of the matching AMG 570 placebo administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced a Clinically Significant Change in Electrocardiograms (ECGs)</title>
          <description>Any changes in ECG parameters that were deemed clinically significant by the Investigator were reported.</description>
          <population>Safety analysis set: all participants who received AMG 570 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) of AMG 570</title>
        <description>AMG 570 pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.</description>
        <time_frame>Pre-dose and 12 hours post-dose on Day 1 and days 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 57, 71 and 105</time_frame>
        <population>The PK concentration analysis set: all participants who received AMG 570 and had at least one quantifiable PK sample collected.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 570 - 7 mg</title>
            <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>AMG 570 - 21 mg</title>
            <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>AMG 570 - 70 mg</title>
            <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>AMG 570 - 140 mg</title>
            <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>AMG 570 - 210 mg</title>
            <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O6">
            <title>AMG 570 - 420 mg</title>
            <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O7">
            <title>AMG 570 - 700 mg</title>
            <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of AMG 570</title>
          <description>AMG 570 pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.</description>
          <population>The PK concentration analysis set: all participants who received AMG 570 and had at least one quantifiable PK sample collected.</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08664" spread="0.0539"/>
                    <measurement group_id="O2" value="0.624" spread="0.327"/>
                    <measurement group_id="O3" value="4.33" spread="3.53"/>
                    <measurement group_id="O4" value="6.05" spread="3.26"/>
                    <measurement group_id="O5" value="17.2" spread="3.78"/>
                    <measurement group_id="O6" value="33.5" spread="15.9"/>
                    <measurement group_id="O7" value="58.5" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Concentration (Tmax) of AMG 570</title>
        <description>AMG 570 PK parameters were estimated using non-compartmental analysis.</description>
        <time_frame>Pre-dose and 12 hours post-dose on Day 1 and days 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 57, 71 and 105</time_frame>
        <population>The PK concentration analysis set: all participants who received AMG 570 and had at least one quantifiable PK sample collected.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 570 - 7 mg</title>
            <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>AMG 570 - 21 mg</title>
            <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>AMG 570 - 70 mg</title>
            <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>AMG 570 - 140 mg</title>
            <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>AMG 570 - 210 mg</title>
            <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O6">
            <title>AMG 570 - 420 mg</title>
            <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O7">
            <title>AMG 570 - 700 mg</title>
            <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Concentration (Tmax) of AMG 570</title>
          <description>AMG 570 PK parameters were estimated using non-compartmental analysis.</description>
          <population>The PK concentration analysis set: all participants who received AMG 570 and had at least one quantifiable PK sample collected.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.0" upper_limit="13"/>
                    <measurement group_id="O3" value="3.0" lower_limit="0.5" upper_limit="5.0"/>
                    <measurement group_id="O4" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="5.0" lower_limit="3.0" upper_limit="10"/>
                    <measurement group_id="O6" value="5.0" lower_limit="3.0" upper_limit="14"/>
                    <measurement group_id="O7" value="5.0" lower_limit="3.0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast) of AMG 570</title>
        <description>AMG 570 PK parameters were estimated using non-compartmental analysis.</description>
        <time_frame>Pre-dose and 12 hours post-dose on Day 1 and days 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 57, 71 and 105</time_frame>
        <population>The PK concentration analysis set: all participants who received AMG 570 and had at least one quantifiable PK sample collected.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 570 - 7 mg</title>
            <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>AMG 570 - 21 mg</title>
            <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>AMG 570 - 70 mg</title>
            <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>AMG 570 - 140 mg</title>
            <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>AMG 570 - 210 mg</title>
            <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O6">
            <title>AMG 570 - 420 mg</title>
            <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O7">
            <title>AMG 570 - 700 mg</title>
            <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast) of AMG 570</title>
          <description>AMG 570 PK parameters were estimated using non-compartmental analysis.</description>
          <population>The PK concentration analysis set: all participants who received AMG 570 and had at least one quantifiable PK sample collected.</population>
          <units>day*µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.591" spread="0.321"/>
                    <measurement group_id="O2" value="5.12" spread="2.62"/>
                    <measurement group_id="O3" value="43.8" spread="26.1"/>
                    <measurement group_id="O4" value="88.3" spread="50.1"/>
                    <measurement group_id="O5" value="271" spread="61.3"/>
                    <measurement group_id="O6" value="561" spread="221"/>
                    <measurement group_id="O7" value="1660" spread="759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve Observed From Time Zero to Infinity (AUCinf) of AMG 570</title>
        <time_frame>Pre-dose and 12 hours post-dose on Day 1 and days 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 57, 71 and 105</time_frame>
        <population>The PK concentration analysis set: all participants who received AMG 570 and had at least one quantifiable PK sample collected.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 570 - 7 mg</title>
            <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>AMG 570 - 21 mg</title>
            <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>AMG 570 - 70 mg</title>
            <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>AMG 570 - 140 mg</title>
            <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>AMG 570 - 210 mg</title>
            <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O6">
            <title>AMG 570 - 420 mg</title>
            <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O7">
            <title>AMG 570 - 700 mg</title>
            <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve Observed From Time Zero to Infinity (AUCinf) of AMG 570</title>
          <population>The PK concentration analysis set: all participants who received AMG 570 and had at least one quantifiable PK sample collected.</population>
          <units>day*µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.928" spread="0.248"/>
                    <measurement group_id="O2" value="6.24" spread="2.76"/>
                    <measurement group_id="O3" value="51.1" spread="21.9"/>
                    <measurement group_id="O4" value="88.6" spread="50.1"/>
                    <measurement group_id="O5" value="284" spread="59.2"/>
                    <measurement group_id="O6" value="624" spread="176"/>
                    <measurement group_id="O7" value="1660" spread="757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Anti-AMG 570 Binding Antibody Positive Postbaseline Result</title>
        <description>The presence of anti-AMG 570 binding antibodies was assessed using a validated assay. The number and percentage of participants who developed binding anti-AMG 570 antibodies at any postbaseline visit are presented.</description>
        <time_frame>Baseline to Day 105</time_frame>
        <population>All participants who received AMG 570 and had a negative or no result for binding antibodies at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 570 - 7 mg</title>
            <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>AMG 570 - 21 mg</title>
            <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>AMG 570 - 70 mg</title>
            <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>AMG 570 - 140 mg</title>
            <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>AMG 570 - 210 mg</title>
            <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O6">
            <title>AMG 570 - 420 mg</title>
            <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O7">
            <title>AMG 570 - 700 mg</title>
            <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Anti-AMG 570 Binding Antibody Positive Postbaseline Result</title>
          <description>The presence of anti-AMG 570 binding antibodies was assessed using a validated assay. The number and percentage of participants who developed binding anti-AMG 570 antibodies at any postbaseline visit are presented.</description>
          <population>All participants who received AMG 570 and had a negative or no result for binding antibodies at baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Peripheral Blood B7-Related Protein-1 (B7RP-1) Receptor Occupancy on Total B Cells</title>
        <description>Peripheral B7RP1 (also known as inducible costimulator ligand [ICOSL]) receptor occupancy was calculated from the free ICOSL and total ICOSL measurement from B cells in whole blood.</description>
        <time_frame>Day 8; Day 29; Day 57; and Day 105</time_frame>
        <population>The pharmacodynamic (PD) analysis set: all participants who had received AMG 570 or placebo and for whom at least one PD parameter had quantifiable baseline sample and a quantifiable PD sample collected at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 570 - 7 mg</title>
            <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>AMG 570 - 21 mg</title>
            <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>AMG 570 - 70 mg</title>
            <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>AMG 570 - 140 mg</title>
            <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>AMG 570 - 210 mg</title>
            <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O6">
            <title>AMG 570 - 420 mg</title>
            <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O7">
            <title>AMG 570 - 700 mg</title>
            <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received a single dose of the matching AMG 570 placebo administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Peripheral Blood B7-Related Protein-1 (B7RP-1) Receptor Occupancy on Total B Cells</title>
          <description>Peripheral B7RP1 (also known as inducible costimulator ligand [ICOSL]) receptor occupancy was calculated from the free ICOSL and total ICOSL measurement from B cells in whole blood.</description>
          <population>The pharmacodynamic (PD) analysis set: all participants who had received AMG 570 or placebo and for whom at least one PD parameter had quantifiable baseline sample and a quantifiable PD sample collected at each specified visit.</population>
          <units>Percentage B7RP-1 receptor occupancy</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.73" spread="8.81"/>
                    <measurement group_id="O2" value="43.76" spread="16.90"/>
                    <measurement group_id="O3" value="64.37" spread="14.80"/>
                    <measurement group_id="O4" value="80.82" spread="6.60"/>
                    <measurement group_id="O5" value="88.87" spread="1.83"/>
                    <measurement group_id="O6" value="92.52" spread="1.52"/>
                    <measurement group_id="O7" value="95.97" spread="1.85"/>
                    <measurement group_id="O8" value="-0.98" spread="13.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="19.12"/>
                    <measurement group_id="O2" value="20.98" spread="16.60"/>
                    <measurement group_id="O3" value="19.96" spread="10.94"/>
                    <measurement group_id="O4" value="38.30" spread="9.95"/>
                    <measurement group_id="O5" value="72.96" spread="9.21"/>
                    <measurement group_id="O6" value="86.64" spread="4.12"/>
                    <measurement group_id="O7" value="89.60" spread="9.00"/>
                    <measurement group_id="O8" value="0.27" spread="14.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="14.27"/>
                    <measurement group_id="O2" value="11.28" spread="9.20"/>
                    <measurement group_id="O3" value="10.14" spread="8.50"/>
                    <measurement group_id="O4" value="6.74" spread="5.47"/>
                    <measurement group_id="O5" value="4.55" spread="15.36"/>
                    <measurement group_id="O6" value="33.20" spread="20.56"/>
                    <measurement group_id="O7" value="65.88" spread="31.67"/>
                    <measurement group_id="O8" value="0.85" spread="14.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 105</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.94" spread="26.16"/>
                    <measurement group_id="O2" value="4.53" spread="10.31"/>
                    <measurement group_id="O3" value="-4.54" spread="8.76"/>
                    <measurement group_id="O4" value="1.37" spread="4.45"/>
                    <measurement group_id="O5" value="-2.25" spread="8.94"/>
                    <measurement group_id="O6" value="-0.08" spread="7.93"/>
                    <measurement group_id="O7" value="13.33" spread="17.05"/>
                    <measurement group_id="O8" value="-2.90" spread="15.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline for Cluster of Differentiation (CD)19+ Total B Cells Counts</title>
        <time_frame>Baseline to Day 8; Day 29; Day 57 and Day 105</time_frame>
        <population>The pharmacodynamic (PD) analysis set: all participants who had received AMG 570 or placebo and for whom at least one PD parameter had quantifiable baseline sample and a quantifiable PD sample collected at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 570 - 7 mg</title>
            <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>AMG 570 - 21 mg</title>
            <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>AMG 570 - 70 mg</title>
            <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>AMG 570 - 140 mg</title>
            <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>AMG 570 - 210 mg</title>
            <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O6">
            <title>AMG 570 - 420 mg</title>
            <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O7">
            <title>AMG 570 - 700 mg</title>
            <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received a single dose of the matching AMG 570 placebo administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline for Cluster of Differentiation (CD)19+ Total B Cells Counts</title>
          <population>The pharmacodynamic (PD) analysis set: all participants who had received AMG 570 or placebo and for whom at least one PD parameter had quantifiable baseline sample and a quantifiable PD sample collected at each specified visit.</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage change from Baseline at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.333" spread="73.517"/>
                    <measurement group_id="O2" value="53.770" spread="43.216"/>
                    <measurement group_id="O3" value="66.531" spread="28.057"/>
                    <measurement group_id="O4" value="32.861" spread="21.296"/>
                    <measurement group_id="O5" value="57.123" spread="75.399"/>
                    <measurement group_id="O6" value="57.478" spread="28.365"/>
                    <measurement group_id="O7" value="74.509" spread="70.354"/>
                    <measurement group_id="O8" value="2.671" spread="20.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change from Baseline at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.284" spread="22.310"/>
                    <measurement group_id="O2" value="-8.084" spread="10.212"/>
                    <measurement group_id="O3" value="-17.994" spread="15.582"/>
                    <measurement group_id="O4" value="-10.047" spread="19.791"/>
                    <measurement group_id="O5" value="22.735" spread="51.384"/>
                    <measurement group_id="O6" value="26.305" spread="28.795"/>
                    <measurement group_id="O7" value="9.637" spread="28.555"/>
                    <measurement group_id="O8" value="3.031" spread="23.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change from Baseline at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.548" spread="41.873"/>
                    <measurement group_id="O2" value="-14.215" spread="14.903"/>
                    <measurement group_id="O3" value="-27.494" spread="20.918"/>
                    <measurement group_id="O4" value="-37.481" spread="17.440"/>
                    <measurement group_id="O5" value="0.386" spread="50.044"/>
                    <measurement group_id="O6" value="-8.882" spread="21.936"/>
                    <measurement group_id="O7" value="1.212" spread="42.870"/>
                    <measurement group_id="O8" value="5.726" spread="28.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change from Baseline at Day 105</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.143" spread="22.117"/>
                    <measurement group_id="O2" value="17.010" spread="33.957"/>
                    <measurement group_id="O3" value="-16.872" spread="19.064"/>
                    <measurement group_id="O4" value="0.841" spread="48.458"/>
                    <measurement group_id="O5" value="-8.111" spread="32.077"/>
                    <measurement group_id="O6" value="-24.059" spread="25.753"/>
                    <measurement group_id="O7" value="-30.413" spread="26.863"/>
                    <measurement group_id="O8" value="1.023" spread="13.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline for CD19+ Total B Cells Percentages (%)</title>
        <time_frame>Baseline to Day 8; Day 29; Day 57 and Day 105</time_frame>
        <population>The PD analysis set: all participants who had received AMG 570 or placebo and for whom at least one PD parameters had quantifiable baseline sample and at quantifiable PD sample collected at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 570 - 7 mg</title>
            <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>AMG 570 - 21 mg</title>
            <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>AMG 570 - 70 mg</title>
            <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>AMG 570 - 140 mg</title>
            <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>AMG 570 - 210 mg</title>
            <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O6">
            <title>AMG 570 - 420 mg</title>
            <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O7">
            <title>AMG 570 - 700 mg</title>
            <description>Participants received a single 700 mg dose of AMG 570 administered subcutaneously.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received a single dose of the matching AMG 570 placebo administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline for CD19+ Total B Cells Percentages (%)</title>
          <population>The PD analysis set: all participants who had received AMG 570 or placebo and for whom at least one PD parameters had quantifiable baseline sample and at quantifiable PD sample collected at each specified visit.</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage change from Baseline at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.111" spread="88.264"/>
                    <measurement group_id="O2" value="24.057" spread="10.041"/>
                    <measurement group_id="O3" value="28.291" spread="16.950"/>
                    <measurement group_id="O4" value="20.942" spread="7.799"/>
                    <measurement group_id="O5" value="26.538" spread="28.906"/>
                    <measurement group_id="O6" value="45.886" spread="25.595"/>
                    <measurement group_id="O7" value="23.693" spread="21.414"/>
                    <measurement group_id="O8" value="-1.241" spread="12.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change from Baseline at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.714" spread="17.368"/>
                    <measurement group_id="O2" value="-13.258" spread="17.292"/>
                    <measurement group_id="O3" value="-22.000" spread="9.603"/>
                    <measurement group_id="O4" value="-5.778" spread="12.947"/>
                    <measurement group_id="O5" value="2.765" spread="28.960"/>
                    <measurement group_id="O6" value="7.836" spread="20.250"/>
                    <measurement group_id="O7" value="4.063" spread="15.629"/>
                    <measurement group_id="O8" value="-0.582" spread="17.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change from Baseline at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.484" spread="84.641"/>
                    <measurement group_id="O2" value="-21.751" spread="11.893"/>
                    <measurement group_id="O3" value="-26.000" spread="20.346"/>
                    <measurement group_id="O4" value="-36.293" spread="18.635"/>
                    <measurement group_id="O5" value="-16.667" spread="35.355"/>
                    <measurement group_id="O6" value="-10.467" spread="4.058"/>
                    <measurement group_id="O7" value="-7.500" spread="19.632"/>
                    <measurement group_id="O8" value="0.167" spread="16.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change from Baseline at Day 105</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.738" spread="8.988"/>
                    <measurement group_id="O2" value="-1.524" spread="17.352"/>
                    <measurement group_id="O3" value="-23.333" spread="14.530"/>
                    <measurement group_id="O4" value="-9.947" spread="17.880"/>
                    <measurement group_id="O5" value="-15.152" spread="13.165"/>
                    <measurement group_id="O6" value="-23.966" spread="13.136"/>
                    <measurement group_id="O7" value="-35.474" spread="10.308"/>
                    <measurement group_id="O8" value="3.895" spread="16.653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 105 days</time_frame>
      <desc>All-cause mortality is reported for all participants enrolled/randomized in the study. Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>AMG 570 - 7 mg</title>
          <description>Participants received a single dose 7 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="E2">
          <title>AMG 570 - 21 mg</title>
          <description>Participants received a single 21 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="E3">
          <title>AMG 570 - 70 mg</title>
          <description>Participants received a single 70 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="E4">
          <title>AMG 570 - 140 mg</title>
          <description>Participants received a single 140 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="E5">
          <title>AMG 570 - 210 mg</title>
          <description>Participants received a single 210 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="E6">
          <title>AMG 570 - 420 mg</title>
          <description>Participants received a single 420 mg dose of AMG 570 administered subcutaneously.</description>
        </group>
        <group group_id="E7">
          <title>AMG 570 - 700 mg</title>
          <description>Participants received 700 mg dose of AMG 570 administered as single dose subcutaneous in healthy volunteers.</description>
        </group>
        <group group_id="E8">
          <title>Placebo</title>
          <description>Participants received a single dose of the matching AMG 570 placebo administered subcutaneously.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

